CCR2 Protein-VLP (AA 1-360) (Biotin)

Catalog No. ABIN7448154

Product Details

Target: CCR2 (Chemokine (C-C Motif) Receptor 2 (CCR2))

Protein Type: VLP

Biological Activity: Active

Protein Characteristics: AA 1-360

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This CCR2 protein is labelled with Biotin.

Application: ELISA, Immunogen (Imm), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Purpose: Biotinylated Human CCR2b Protein-VLP

Sequence: Met1-Leu360

Characteristics: Recombinant Biotinylated Human CCR2b Protein-VLP is expressed from HEK293.It contains Met1-Leu360.

Purity: > 95 % as determined by HPLC

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1EU per μg by the LAL method.

Biological Activity Comment: The affinity constant of 5.24 nM as determined in SPR assay (Biacore T200).

Application Details

Application Notes:

• Antibody Discovery: Immunization, Screening, Functional Characterization
• Affinity determination: ELISA, SPR
• In vivo pharmacokinetic analysis
• CMC method development
• CAR-T Positive Rate Detection
• Blood sample determination: ELISA

Comment:

Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Supplied as 0.22μm filtered solution in PBS ( pH 7.4).

Storage: -80 °C

Storage Comment: Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: CCR2 (Chemokine (C-C Motif) Receptor 2 (CCR2))

Alternative Name: CCR2b (CCR2 Products)

Synonyms: CC-CKR-2 Protein, CCR-2 Protein, CCR2A Protein, CCR2B Protein, CD192 Protein, CKR2 Protein, CKR2A Protein, CKR2B Protein, CMKBR2 Protein, MCP-1-R Protein, ACKR5 Protein, CKRX Protein, CRAM Protein, CRAM-A Protein, CRAM-B Protein, HCR Protein, Cc-ckr-2 Protein, Ccr2a Protein, Ccr2b Protein, Ckr2 Protein, Ckr2a Protein, Ckr2b Protein, Cmkbr2 Protein, mJe-r Protein, C-C motif chemokine receptor 2 Protein, C-C motif chemokine receptor like 2 Protein, chemokine (C-C motif) receptor 2 Protein, CCR2 Protein, CCRL2 Protein, Ccr2 Protein, LOC484790 Protein

Background: The chemokine (C-C motif) receptor 2B (CCR2B) is one of the two isoforms of the receptor for monocyte chemoattractant protein-1 (CCL2), the major chemoattractant for monocytes, involved in an array of chronic inflammatory diseases. The actin-binding protein filamin A (FLNa) as a protein that associates with the carboxyl-terminal tail of CCR2B. FLNa emerges as an important protein for controlling the internalization and spatial localization of the CCR2B receptor in different dynamic membrane structures.

Molecular Weight: 42.9kDa.

Pathways: cAMP Metabolic Process, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process